Comparative study of the effect of PTH (1-84) and strontium ranelate in an experimental model of atrophic nonunion

Injury. 2015 Dec;46(12):2359-67. doi: 10.1016/j.injury.2015.10.007. Epub 2015 Oct 29.

Abstract

This study aimed to set up an experimental model of long bone atrophic nonunion and to explore the potential role of PTH-1-84 (PTH 1-84) and strontium ranelate (SrR). A model of atrophic nonunion was created in Sprague-Dawley rats at the femoral midshaft level. The animals were randomised into four groups. Group A1: control rodents, fracture without bone gap; Group A2: rodents with subtraction osteotomy (non-union model control) treated with saline; Group B: rodents with subtraction osteotomy treated with human-PTH (PTH 1-84); and Group C: rodents with subtraction osteotomy treated with strontium ranelate (SrR). The groups were followed for 12 weeks. X-rays were be obtained at weeks 1, 6 and 12. After sacrificing the animals, we proceeded to the biomechanical study and four point bending tests to evaluate the resistance of the callus and histological study. In second phase, the expression of genes related to osteoblast function was analysed by reverse transcription-quantitative PCR in rats subjected to substraction osteotomy and treated for 2 weeks. The animals were randomised into three groups: Group A2: rodents treated with saline; Group B: rodents treated with PTH 1-84 and Group C: rodents treated with SrR.

Results: No significant histological differences were found between animals subjected to subtraction osteotomy and treated with either saline or PTH (p=0.628), but significant difference existed between animals receiving saline or SrR (p=0.005). There were no significant differences in X-ray score between the saline and PTH groups at either 6 or 12 weeks (p=0.33 and 0.36, respectively). On the other hand, better X-ray scores were found in the SrR group (p=0.047 and 0.006 in comparison with saline, at 6 and 12 weeks, respectively). In line with this, biomechanical tests revealed improved results in the SrR group. Gene expression analysis revealed a slightly decreased levels of DKK1, a Wnt pathway inhibitor, in rats treated with SrR.

Conclusions: SrR increases has a beneficial effect in this atrophic non-union model in rats. This suggests that it might have a role may have important implications for the potential clinical role in the treatment of fracture nonunion.

Keywords: Atrophic nonunion bone repair; Experimental pseudoartrosis; Fracture gap; Human PTH 1–84 (PTH 1–84); Strontium ranelate (SrR).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Density Conservation Agents / pharmacology*
  • Disease Models, Animal
  • Femoral Fractures / pathology*
  • Fracture Healing
  • Fractures, Malunited / pathology*
  • Osteotomy
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Teriparatide / analogs & derivatives*
  • Teriparatide / pharmacology
  • Thiophenes / pharmacology*
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Peptide Fragments
  • Thiophenes
  • strontium ranelate
  • Teriparatide
  • parathyroid hormone (1-34)amide